Literature DB >> 32153778

Predictors of chronic kidney disease in obstructive sleep apnea patients.

Phunphai Somkearti1, Paiboon Chattakul1, Sittichai Khamsai1, Panita Limpawattana1, Jarin Chindaprasirt1, Verajit Chotmongkol1, Kittisak Sawanyawisuth1.   

Abstract

INTRODUCTION: Obstructive sleep apnea (OSA) is a common condition in patients with chronic kidney disease (CKD). It may worsen renal function in CKD patients and is associated with uncontrolled blood pressure. Although OSA is found in up to 80% of CKD patients, there are limited data available on its clinical features in patients with and without CKD.
OBJECTIVE: This study aimed to identifying the differences in the clinical characteristics of OSA between CKD and non-CKD OSA patients and determine the clinical predictors for CKD in OSA patients.
METHODS: This was a retrospective study conducted at Khon Kaen University's Srinagarind Hospital in Thailand between July and December 2018. The inclusion criteria were diagnosis with OSA via polysomnography and having undergone laboratory tests for CKD. Obstructive sleep apnea is diagnosed according to the apnea-hypopnea index (AHI) as experiencing ≥5 events/hour, while CKD diagnosed based on the KDOQI guidelines. Eligible patients were divided into two groups: OSA with CKD and OSA without CKD. Predictors of CKD in OSA patients were analyzed using multivariate logistic regression analysis.
RESULTS: During the study period, there were 178 OSA patients who met the study criteria, 88 (49.44%) of whom were in the OSA with CKD group. Both age and body mass index were comparable between OSA patients with CKD and those without (age: 59 and 57 years, respectively; body mass index: 30 and 29 kg/m2, respectively. There were three significant factors that differed between those with and without CKD group including systolic blood pressure (147 vs 135 mmHg), proportion of patients with diabetes (55% vs 34%), and proportion of patients with Mallampati scores of 3-4 (73% vs 39%). There were three independent predictors for OSA in patients with CKD: female sex, high systolic blood pressure, and Mallampati score of 3 or 4, with adjusted odds ratios (95% confidence interval) of 4.624 (1.554, 13.750), 1.060 (1.020, 1.101), and 2.816 (1.356, 5.849), respectively. The Hosmer-Lemeshow chi-square statistic of the predictive model was 6.06 (p 0.640). Systolic blood pressure of more than 130 and 150 mmHg resulted in sensitivity of 84.21% and specificity of 81.40%, respectively.
CONCLUSIONS: Female sex, high systolic blood pressure, and Mallampati score of 3-4 were suggestive of OSA with CKD. Obstructive sleep apnea patients with one or more of these predictors may have a high risk of CKD. ©Copyright: the Author(s), 2020.

Entities:  

Keywords:  Predictors; sex; systolic blood pressure

Year:  2020        PMID: 32153778      PMCID: PMC7037503          DOI: 10.4081/mrm.2020.470

Source DB:  PubMed          Journal:  Multidiscip Respir Med        ISSN: 1828-695X


Introduction

Obstructive sleep apnea (OSA) is categorized by cyclic obstruction of the upper airway during sleep. It has various clinical manifestations, from loud snoring, excessive daytime somnolence, and apneas. The condition is diagnosed via polysomnography according to the apnea-hypopnea index (AHI) as experiencing ≥5 events/hour [1]. Obstructive sleep apnea can exacerbate various other conditions such as hypertension, heart failure, stroke, gastroesophageal reflux disease, and chronic kidney disease (CKD) [2]. There is evidence of a bidirectional relationship between OSA and CKD. Chronic kidney disease may potentiate sleep apnea due to fluid redistribution and unstable chemosensitivity of the respiratory control system, while hypoxemia and sympathetic surges associated with arousals and systemic inflammation in OSA may lead to kidney injury [3]. Obstructive sleep apnea is found in nearly 80% in CKD patients [4] and some studies have suggested that OSA is a risk factor for CKD [5-7]. A study from Japan, for example, found that 30.5% of OSA patients had CKD, a rate three times greater than that in the general population (9.1%) [8]. It is difficult to draw the conclusion that worsening kidney function in these patients is solely a result of OSA as they usually have other comorbidities including diabetes mellitus, obesity, and hypertension. However, a cohort study from Taiwan showed that even those OSA patients without hypertension or diabetes were at higher risk of developing CKD and experienced earlier onset of CKD compared to a control group [9]. Although OSA and CKD are related, there are limited data available regarding the factors that predict CKD in OSA patients. This study thus aimed to determine the clinical predictors for CKD in those patients.

Methods

We conducted a retrospective, cross-sectional, analytic study at Khon Kaen University’s Srinagarind Hospital in Thailand. The study period was between July and December 2018. The inclusion criteria were i) age ≥18 years; ii) having been diagnosed with OSA via polysomnography; and iii) having undergone laboratory tests for CKD. Obstructive sleep apnea is diagnosed according to the apnea-hypopnea index (AHI) as experiencing ≥5 events/hour, while CKD is diagnosed based on the KDOQI guidelines. The polysomnography used in this study was Alice PDX® as a home sleep study (Type 3 polysomnography) which had agreement of 96.4% with reference polysomnography. The scoring criteria for apnea and hypopnea are as follows: apnea: at least a 90% reduction of airflow for at least 10 seconds with at least 90% of the event’s duration meets the amplitude reduction criteria for apnea, hypopnea: either ≥30% reduction in airflow for at least 10s with ≥4% desaturation or ≥50% reduction in airflow for at least 10s with ≥3% desaturation [10]. Baseline characteristics, comorbidities, OSA symptoms/ signs/complications, and laboratory results of all eligible patients were examined and recorded. All data were recorded at the time of OSA diagnosis. Excessive daytime sleepiness or other OSA symptoms were evaluated by subjective evaluation or self-reported questionnaire by using the STOP Bang questionnaire. Sample size calculation: the prevalence of CKD in cases of OSA is 30%. Based on a 95% confidence interval, the required sample size was determined to be 82 according to the infinite population proportion described by Ngamjarus et al. [11]. Statistical analysis: baseline and clinical characteristics of OSA patients with and without CKD were compared using descriptive statistics. When appropriate, a Wilcoxon rank sum/Student’s t-test and Fisher’s exact tests/chi-square test were applied to compare the differences between the two groups in terms of numbers and proportions, respectively. Univariate logistic regression analysis was applied to calculate the crude odds ratio (OR) of individual variables for OSA associated with CKD. Those factors with a p of less than 0.20 by univariate logistic regression analysis and clinically significant variables were included in subsequent multivariate logistic regression analysis. Analytical results were presented as crude OR, adjusted OR, and 95% confidence intervals. The goodness of fit of the multivariate logistic regression model was tested using the Hosmer-Lemeshow method. Numerical independent factors for OSA associated with CKD were analyzed for appropriate cutoff points. Sensitivities and specificities for various cutoff points for CKD were also computed. All data analysis was performed using STATA software (StataCorp LP, College Station, TX, USA). The study was reviewed and approved by the Khon Kaen University Ethics Committee of Human Research (no. HE611131).

Results

There were 178 OSA patients included into the study, 88 (49.44%) of whom had CKD. The baseline characteristics, physical signs, and laboratory results of OSA patients with and without CKD are shown in Tables 1-3. For the CKD group, were 45 patients (51.13%) with identified causes of CKD as follows: 31 patients with albuminuria, 10 patients with proteinuria >1 gm, 2 patients with obstructive uropathy, 1 patient with IgA nephropathy, and 1 patient with focal segmental glomerulosclerosis (FSGS). Additionally, 10 patients were on dialysis. Baseline characteristics of the two groups were comparable. For example, median age was 59 vs 57, and body mass index was 30 vs 29 kg/m2 in the CKD and non-CKD group, respectively. However, the proportion of patients with hypertension and diabetes mellitus differed significantly between the two groups (81% vs 58% for hypertension with a p of <0.001 and 55.29% vs 34.62% for diabetes mellitus with a p of 0.012). As shown in Table 2, OSA patients with CKD had significantly higher systolic blood pressure than those without (147 vs 135 mmHg; p<0.001). The proportions of patients with Mallampati scores of 3-4 were also significantly different between the two groups (73% vs 39%; p<0.001). In addition, apnea-hypopnea index (AHI) scores were significantly higher in the CKD group than in the non-CKD group (23.5 vs 14 events/h; p=0.006), as shown in Table 3. Other laboratory results in which there were significant differences between the two groups include UACR, uric acid, and neutrophil and lymphocyte percentages (Table 3).
Table 2.

Physical signs of obstructive sleep apnea patients with and without chronic kidney disease.

FactorCKDNon-CKDp
(n=88)(n=90)
Body mass index, kg/m230.4(26.27-35)29(25.4-33.1)0.248
Neck circumference, cm41(39-45)41(39-44)0.911
Median (1st-3rd quartile) SBP, mmHg146.5(134-156)135(123-146)<0.001
Median (1st-3rd quartile) DBP, mmHg80(70-86)79(72-85)0.929
Median (1st-3rd quartile) BMI, kg/m230.4 (26.27-35)29(25.4-33.1)0.248
Median (1st-3rd quartile)41(39.0-45.0)41(39.0-44.0)0.911
neck circumference, cm
Mallampati classification<0.001
    Class I2(3.85)10(16.39)
    Class II12(23.08)27(44.26)
    Class III24(46.15)21(34.43)
    Class IV14(26.92)3(4.92)
Macroglossia23(34.85)23(31.08)0.719
Torus palatinus1(1.56)8(11.11)0.036
Torus mandibularis2(3.17)4(5.71)0.683
Tonsillar enlargement28(31.82)36(40.00)0.277
Microretrognathia2(3.13)2(2.74)0.990
Retrognathia3(4.92)5(7.04)0.725

CKD, chronic kidney disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index. Data are presented as number (percentage) unless indicated otherwise.

Table 3.

Laboratory investigation results of obstructive sleep apnea (OSA) patients with and without chronic kidney disease.

FactorCKDNon-CKDp
(n=88)(n=90)
Blood urea nitrogen, mg/dL21.1(13.7-38.3)13.3(11.5-15.7)<0.001
Serum creatinine, mg/dL1.4(1.1-2.45)0.9(0.76-1.1)<0.001
GFR47.5(28-66.5)85.5(73-99.7)<0.001
Uric, mg/dL7.2(5.9-8.3)6.1(5.2-7)0.002
UACR, mg/g93.5(29.2-560.2)4.64(2.4-12.01)<0.001
HbA1C, %6.6(5.65-8.25)6.1(5.5-7)0.060
Cholesterol, mg/dL179(152-209)195(170-220)0.149
Triglyceride, mg/dL147(87-188)148(97-202)0.448
HDL-c, mg/dL, mg/dL47(39-56)48(42-59)0.149
LDL-c, mg/dL, mg/dL117(93-159)130(96-158)0.288
Neutrophil, %61.8(53.6-65.6)53.8(48.4-60.8)0.002
Lymphocyte, %26.7(20.4-30.8)30.9(27-37.2)0.001
Platelet, mm3242x103(203-282)233x103(188-282)0.311
LVEF, %66(58-70)67(62-75)0.475
RVSP, mmHg29.59(19.9-51.73)28.66(21.1-46.97)0.899
AHI, per hour23.5(14.7-47)14(9-30)0.006
Severity of OSA, %0.006
    Mild52%
    Moderate21%
    Severe27%
Lowest O2, %85(73-90)0.338

CKD, chronic kidney disease; HDL-c, high density lipoprotein-cholesterol; LDL-c, low density lipoprotein-cholesterol; UCAR, urine albumin creatinine ratio; LVEF, Left ventricular ejection fraction; RVSP, right ventricular systolic pressure; AHI, apnea hypopnea index. Data presented as median (1st-3rd percentile) unless indicated otherwise.

There were three independent predictors for CKD in OSA patients according to multivariate regression analysis: sex, systolic blood pressure, and Mallampati classification (Table 4), with odds ratios (95% confidence interval) of 4.624 (1.554, 13.757), 1.060 (1.020, 1.101), and 2.816 (1.356, 5.849), respectively. The Hosmer-Lemeshow chi-square of the predictive model was 6.06 (p=0.640). Systolic blood pressure of 130 and 150 mmHg cut points resulted in sensitivity of 84.21% and specificity of 81.40%, respectively.
Table 4.

Factors associated with chronic kidney disease in obstructive sleep apnea patients according to logistic regression analysis.

FactorsUnadjusted odds ratio (95% confidence interval)Adjusted odds ratio (95% confidence interval)
Female sex[*]1.195(0.655,4.624)4.624(1.554,13.750)
SBP, mmHg[*]1.039(1.019,1.060)1.060(1.020,1.101)
Mallampati classification[*]2.829(1.676,4.776)2.816(1.356,5.849)
Diabetes mellitus2.336(1.240,4.398)0.934(0.312,2.792)
Body mass index, kg/m21.028(0.981,1.076)0.994(0.911,1.086)

*Independent predictor for chronic kidney disease in obstructive sleep apnea; SBP, systolic blood pressure.

Baseline characteristic of obstructive sleep apnea patients with and without chronic kidney disease. CKD, chronic kidney disease. Data are presented as number (percentage) unless indicated otherwise.

Discussion

We found that female OSA patients tended to have a five-times higher risk of CKD than their male counterparts. Sex is an important factor that affects prevalence, clinical features, and clinical outcomes [12]. However, the reason for this correlation has yet to be explained. One possible explanation is that OSA symptoms in female patients tend to be less severe, leading these patients to seek medical treatment later and resulting in greater CKD development [13]. Another reason may have to do with endothelial dysfunction and inflammation [14-16]. Hypoxemia may stimulate the release of cytokine and free radical products in OSA patients, which leads to a reductions in nitric oxide. Previous studies have found that high levels of various inflammatory proteins are significantly correlated with OSA severity. Surprisingly, increases in C-reactive protein (CRP) levels and the Erythrocyte Sedimentation Rate (ESR) in female OSA patients were found to be greater than those in their male counterparts [17]. Endothelial function was also found to be more sensitive and impaired in female OSA patients than in males. The mechanisms behind this difference have yet to be determined, but menopause may be a factor, as estrogen can promote the production of nitric oxide and slow its degradation [18]. Although the mean age of our patients was over 50 years, we were not able to assess their menopause status. The relationship among OSA, hypertension, and CKD is well-documented [19, 20]. Hypoxia due to OSA leads to increases in sympathetic tone and vascular resistance through the activation of the renin angiotensin aldosterone system (RAAS), which is associated with the fibrosis of kidney [20]. Systolic blood pressure was an important predictor for renal disease progression in this study, which is consistent with the findings of several previous studies [21,22]. Physical signs of obstructive sleep apnea patients with and without chronic kidney disease. CKD, chronic kidney disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index. Data are presented as number (percentage) unless indicated otherwise. Laboratory investigation results of obstructive sleep apnea (OSA) patients with and without chronic kidney disease. CKD, chronic kidney disease; HDL-c, high density lipoprotein-cholesterol; LDL-c, low density lipoprotein-cholesterol; UCAR, urine albumin creatinine ratio; LVEF, Left ventricular ejection fraction; RVSP, right ventricular systolic pressure; AHI, apnea hypopnea index. Data presented as median (1st-3rd percentile) unless indicated otherwise. Factors associated with chronic kidney disease in obstructive sleep apnea patients according to logistic regression analysis. *Independent predictor for chronic kidney disease in obstructive sleep apnea; SBP, systolic blood pressure. Mallampati score (the estimation of tongue size relative to the oral cavity) was also an independent factor for CKD in this study. A score of 3-4 increased the risk of CKD by nearly 3 times. To our knowledge, this is the first study to identify a high Mallampati score as being a risk factor for CKD development in OSA patients. We suspect that the fluid retention process might play role in increasing the tongue size, a phenomenon that has previously been shown in pregnant women [23]. A large tongue may lower oxygen levels during sleep, leading to a higher chance of developing CKD [24]. However, Mallampati scores are subjective and may vary from examination to examination. We found that if OSA patients had systolic blood pressure over 130 mmHg, sensitivity of having CKD was 84.21%. If the systolic blood pressure was over 150 mmHg, the specificity was 81.40%. These data may imply two points as follows: i) OSA patients with high systolic blood pressure are at risk for CKD. Therefore, the physicians should be aware of CKD in OSA patients with systolic blood pressure over 130 mmHg. ii) OSA patients may need to have a target systolic blood pressure of 130 mmHg to prevent risk of CKD. If the systolic blood pressure was over 150 mmHg, the specificity of having CKD in OSA patients would rise. In other words, the target blood pressure for OSA with hypertension may be appropriate at 130 mmHg. As the target systolic blood pressure has been set for other populations but not in OSA patients [25]. There were some limitations to this study. First, it was conducted in a single-site, referral medical center. Second, the predictive model for CKD included only clinical symptoms and signs and not laboratory results. The benefit of this model, however, is that it can be employed as a simple clinical model for health care facilities with limited resources. Other predictive models that include laboratory results should be developed. No intervention or evaluation of treatment outcomes were studied [26-28]. Due to retrospective data collection, some factors may be missing or not studied such as fluid distribution or menopausal status. Finally, SBP in this study was office blood pressure, and did not take into account home or nighttime blood pressure patterns. Due to the fact that OSA and CKD patients usually have non-dipping blood pressure variations [29], morning blood pressure or home-monitoring blood pressure should be examined further.

Conclusion

Female sex, high systolic blood pressure, and Mallampati classes 3-4 were suggestive of CKD in OSA patients.
Table 1.

Baseline characteristic of obstructive sleep apnea patients with and without chronic kidney disease.

FactorCKDNon-CKDp
(n=88)(n=90)
Male sex51 (57.95)56 (62.2)0.646
Median (1st-3rd quartile) age, years59 (44-66)57 (47-66)0.831
Excessive daytime sleepiness39(68)39 (58.21)0.336
Tiredness or fatigue14 (70.00)38 (80.85)0.352
STOP-BANG questionnaire score5(4-5)5(4-6)0.780
Diabetes mellitus47 (55.29)27(34.62)0.012
Coronary artery disease6 (7.06)0 (0.0)0.029
Heart failure12(14.12)9 (11.54)0.648
Atrial fibrillation15(17.05)16 (17.78)0.995
Hypertension81(95.29)58(74.36)<0.001
Stroke7(8.24)6(7.69)0.99
Gastroesophageal reflux disease14(16.47)12(15.38)0.99
Gout13(15.29)5(6.41)0.083
Allergic rhinitis22(25.88)13(16.67)0.183
Previous smoking10(25.00)12(20.69)0.631
Previous alcohol consumption11(28.95)9(16.07)0.199
Current smoking1(2.50)5(8.93)0.396
Current alcohol consumption1(3.33)4(7.02)0.656

CKD, chronic kidney disease. Data are presented as number (percentage) unless indicated otherwise.

  24 in total

1.  Obstructive sleep apnea syndrome is related to the progression of chronic kidney disease.

Authors:  Asiye Kanbay; Hakan Buyukoglan; Nezihe Ozdogan; Elif Kaya; Fatma Sema Oymak; Inci Gulmez; Ramazan Demir; Oguz Kokturk; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2011-03-03       Impact factor: 2.370

Review 2.  Obstructive Sleep Apnea and Diabetes: A State of the Art Review.

Authors:  Sirimon Reutrakul; Babak Mokhlesi
Journal:  Chest       Date:  2017-05-17       Impact factor: 9.410

3.  Vascular calcification and 25-hydroxyvitamin D levels in non-dialysis patients with chronic kidney disease stages 4 and 5.

Authors:  Cesar García-Canton; Elvira Bosch; Ana Ramírez; Yeray Gonzalez; Ingrid Auyanet; Rita Guerra; Miguel A Perez; Ernesto Fernández; Agustín Toledo; Mar Lago; Maria D Checa
Journal:  Nephrol Dial Transplant       Date:  2010-10-18       Impact factor: 5.992

4.  Obstructive Sleep Apnea and Chronic Kidney Disease.

Authors:  Josef Yayan; Kurt Rasche; Angeliki Vlachou
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

Review 5.  Blood pressure and progression of chronic kidney disease: importance of systolic, diastolic, or diurnal variation.

Authors:  Evelyn Mentari; Mahboob Rahman
Journal:  Curr Hypertens Rep       Date:  2004-10       Impact factor: 5.369

6.  High Prevalence of chronic kidney disease among patients with sleep related breathing disorder (SRBD).

Authors:  Kunitoshi Iseki; Kazuyo Tohyama; Tsuyoshi Matsumoto; Hiroshi Nakamura
Journal:  Hypertens Res       Date:  2008-02       Impact factor: 3.872

7.  Microvascular endothelial dysfunction is associated with albuminuria and CKD in older adults.

Authors:  Stephen L Seliger; Shabnam Salimi; Valerie Pierre; Jamie Giffuni; Leslie Katzel; Afshin Parsa
Journal:  BMC Nephrol       Date:  2016-07-13       Impact factor: 2.388

Review 8.  The association of obstructive sleep apnea and renal outcomes-a systematic review and meta-analysis.

Authors:  Der-Wei Hwu; Kun-Der Lin; Kun-Chen Lin; Yau-Jiunn Lee; Yu-Hung Chang
Journal:  BMC Nephrol       Date:  2017-10-16       Impact factor: 2.388

9.  Evaluation of Inflammatory Markers in a Large Sample of Obstructive Sleep Apnea Patients without Comorbidities.

Authors:  Izolde Bouloukaki; Charalampos Mermigkis; Nikolaos Tzanakis; Eleftherios Kallergis; Violeta Moniaki; Eleni Mauroudi; Sophia E Schiza
Journal:  Mediators Inflamm       Date:  2017-07-31       Impact factor: 4.711

10.  A randomized controlled trial to validate the Alice PDX ambulatory device.

Authors:  Georg Nilius; Ulrike Domanski; Maik Schroeder; Karl-Josef Franke; Anke Hogrebe; Laurent Margarit; Maria Stoica; Marie-Pia d'Ortho
Journal:  Nat Sci Sleep       Date:  2017-06-06
View more
  1 in total

Review 1.  Comprehensive and Safe Decongestion in Acutely Decompensated Heart Failure.

Authors:  Jason Stencel; Indranee Rajapreyar; Rohan Samson; Thierry Le Jemtel
Journal:  Curr Heart Fail Rep       Date:  2022-09-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.